Call | Career Development Fellowship (CDF) |
Programme | EDCTP2 |
Start Date | 2018-08-01 |
End Date | 2022-07-31 |
Project Code | TMA2016CDF1597 |
Status | Active |
Epidemiology, Diagnosis algorithms and prognostic role of Immunologic and Inflammatory Markers among HIV-2 infected individuals in West Africa
This study will be organized into three axes, each with specific objectives. Axis 1: Epidemiology The aim is to provide accurate estimates of HIV-2 prevalence in West Africa using a mixed-method approach. The specific objectives are: • To estimate the prevalence of HIV-2 infection in west African countries using national health and demographic survey data • To estimate the proportion of new HIV-2 infected patients in west African countries based on laboratory surveillance platform • To realize mathematic modification on HIV-2 prevalence worldwide using existing datasets Axis 2: Diagnosis The aim is to improve the diagnosis and classification of HIV-2 and dually infected patients using molecular biology. The specific objectives are: • To confirm the HIV-1 & HIV-2 dual infection using molecular biology To describe the prevalence of dual infections in the WADA HIV-2 cohorts To evaluate a diagnostic algorithm based on rapid HIV tests for the routine diagnosis of dual infection in West Africa Axis 3: Disease progression and inflammatory markers: To describe the proportion and characteristics of long-term non-progressors and elite controllers among HIV-2 infected individuals in the WADA HIV-2 cohort To describe morbidity, disease progression and correlates among HIV-2 infected individuals in West Africa • To describe the temporal evolution of soluble biomarkers of inflammation and the correlation with morbidity and disease progression
Institution | Country |
---|---|
Programme PACCI | Cote D'ivoire |
Name | Institution | Country |
---|---|---|
Pr Andre Inwoley | Félix Houphouet-Boigny University, Abidjan, Côte d’Ivoire; Research and Diagnosis Center for AIDS and other infectious diseases (CeDReS), | Cote D'ivoire |
Pr Didier Ekouevi | University of Lome / Faculty of medecine | Togo |
Dr Patrick Coffie | Department dermatology and infectiology university Felix Ouphouet-Boigny | Cote D'ivoire |
Touré Yelamikan Frank Serge | Programme PACCI | Cote D'ivoire |
Pr Armel Poda | Service des maladies infectieuses CHU SOUROU Sanou | Burkina Faso |
Pr Charlotte Charpentier | INSERM, IAME, UMR 1137, Paris, France ; Université Paris Diderot, Sorbonne Paris Cité, Paris, France ; AP-HP, Hôpital Bichat-Claude Bernard, Service de Virologie, Paris, France | France |
Alexandra Bitty Anderson | University of Bordeaux / Programme PACCI | France |
Evelyne Affi | Félix Houphouet-Boigny University, Abidjan, Côte d’Ivoire; Research and Diagnosis Center for AIDS and other infectious diseases (CeDReS), | Cote D'ivoire |
Axis 1: Epidemiology of HIV-2 infection First we will estimate the prevalence of HIV-2 infection: the estimates of the national prevalence of HIV-2 infection will be based on the testing of the dried blood spot collected during the last national demography and health survey (DHS) organized in selected participating countries where DHS was recently conducted. The HIV diagnosis during the DHS is based on the use of two serial ELISA tests. No discriminative test is used during the DHS laboratory analyses. According to the methodology of DHS in most West African countries, after the survey, the DBS are stored in the referral laboratory till the next DHS round. This survey will be conducted in collaboration with the national HIV program of each participating center. The DBS of HIV positive DHS participants will be collected in each country and transferred to the CEDRES in Côte d’Ivoire, were an indirect immuno-enzymatic test allowing the qualitative detection of both HIV-1 (gp120) and HIV-2 (gp36) antibodies will be performed. This test has been adapted from Francis Barin’s essay for HIV-1 (40), and has shown 98% specificity (41) and 80% concordance with real-time DNA PCR (18). It is approved by the French National AIDS Research Agency (ANRS) and routinely used in the reference laboratory of the study as homemade Elisa.
Centre intégré de Recherche bioclinique d'Abidjan (CIRBA) |
Centre Medical de Suivi des Donneurs de sang (CMSDS) |
Service des Maladies Infectieuses et Tropicales du CHU de Treichville (SMIT) |
Unite des soins ambulatoires et de conseil CHU de Treichville (USAC) |
Centre de Prise en charge de recherche et de Formation (CePReF) |
CHU sourou Sanou Hopital du jour Bobo dioulasso |
Type | Name | Title | University | Start Date | End Date |
---|---|---|---|---|---|
Master | Dominique Oloye | INTERET PRONOSTIQUE DU sVCAM-1 CHEZ LES PERSONNES VIVANT AVEC LE VIH-2 | Félix Houphouet-Boigny University, Abidjan, Côte d’Ivoire | 2019 | 2020 |
PhD | Lionele.Mba Fotsing | Dosage et intérêt pronostic des marqueurs immunologiques et inflammatoires dans le suivi des personnes vivant avec le VIH-2 en Afrique de l’Ouest | Félix Houphouet-Boigny University, Abidjan, Côte d’Ivoire | 2018 | 2021 |
Tchounga BK, Charpentier C, Coffie PA, Dabis F, Descamps D, Eholie SP, et al. (2020) Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d’Ivoire West Africa. PLoS ONE 15(8): e0236642. https://doi.org/ 10.1371/journal.pone.0236642 |
Elizabeth Glazer Pediatric AIDS Foundation / PACCI Research Center
Associate Director of Public Health Evaluation / Project Coordinator
2016 | TMA-CDF 2016 |
2017 | Expertise France FEI 5% / 17SANIN142 |
2014 | 12294-B78 |
Type | Name | Title | University | Start Date | End Date |
---|---|---|---|---|---|
PhD in biology | MBA Fotsing Lionèle | Mrs | University Felix Ouphouet-Boigny of Abidjan | 2019 | 2021 |
Master Biology | Dominique Oloye | Dr | University of Bordeaux | 2019 | 2020 |
Master public health | Koffi Jean Jacques | Dr | University of Bordeaux | 2021 | 2022 |
Role | Committee/board | Start Date | End Date |
---|
Institution | Degree | Year |
---|---|---|
University of Bordeaux, France | PhD | 2016-12-13 |
University of Bordeaux, France | MPH | 2012-09-15 |
University of Abidjan, Cote D'ivoire | MD | 2010-04-10 |
Human Immuno-deficiency Virus (HIV) Tuberculosis (TB) Neglected Infectious Diseases (NID)
The long-term prognosis of HIV-2-infected patients receiving antiretroviral therapy (ART) is still challenging, due to the intrinsic resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) and the suboptimal response to some protease inhibitors (PI). The objective was to describe the 5-years outcomes among HIV-2 patients harboring drug-resistant viruses.
A clinic-based cohort of HIV-2-patients experiencing virologic failure, with at least one drug resistance mutation was followed from January 2012 to August 2017 in Côte d’Ivoire. Follow-up data included death, lost to follow-up (LTFU), immuno-virological responses. The Kaplan-Meier curve was used to estimate survival rates.
A total of 31 HIV-2 patients with virologic failure and with at least one drug resistance mutation were included. Two-third of them were men, 28(90.3%) were on PI-based ART-regimen at enrolment and the median age was 50 years (IQR = 46–54). The median baseline CD4 count and viral load were 456 cells/mm3 and 3.7 log10 c/mL respectively, and the participants have been followed-up in median 57 months (IQR = 24–60). During this period, 21 (67.7%) patients switched at least one antiretroviral drug, including two (6.5%) and three (9.7%) who switched to a PI-based and an integrase inhibitor-based regimen respectively. A total of 10(32.3%) patients died and 4(12.9%) were LTFU. The 36 and 60-months survival rates were 68.5% and 64.9%, respectively. Among the 17 patients remaining in care, six(35.3%) had an undetectable viral load (<50 c/mL) and for the 11 others, the viral load ranged from 2.8 to 5.6 log10 c/mL. Twelve patients were receiving lopinavir at the time of first genotype, five(42%) had a genotypic susceptibility score (GSS) ≤1 and 4(33%) a GSS >2.
The 36-months survival rate among ART-experienced HIV-2 patients with drug-resistant viruses is below 70%,lower than in HIV-1. There is urgent need to improve access to second-line ART for patients living with HIV-2 in West Africa
Name | Country | Institution |
---|---|---|
Boris TCHOUNGA | Cote D'ivoire | PACCI Research Center |
Didier Ekouévi | Togo | University of Lomé / Pacci Research Center |